Yttrium-90 microsphere therapy for hepatocellular carcinoma: Clinical efficacy, mechanistic insights, and comparative therapeutic perspectives

Table 1 Key insights from yttrium-90 microsphere therapy studies

Outcome/parameter	Key findings	Ref.
Overall survival	Median OS: 15-32.2 months	Van Thai et al[1]; Chen et al[2]
Tumor response rate	ORR: 58%-73.3%; CR: 7%-21.9%	Huang et al[3]; Baloji et al[9]
Progression-free survival	Median PFS: 4-8 months	Chen et al[2]; Huang et al[3]
Tumor absorbed dose	Higher TAD (> 150-200 Gy) correlates with better outcomes	Lam et al[6]; Kokabi et al[7]
Adverse events	Grade 3 + toxicity: < 5%; common side effects include abdominal pain and fatigue	Huang et al[3]; Sarwar et al[5]

OS: Overall survival; ORR: Overall response rate; CR: Complete response; PFS: Progression-free survival; TAD: Tumor absorbed dose.